Conventional therapies as well as dietary management using dietary supplements are being used as measures to prevent the development of complications of CVD in diabetes. Sources of dietary supplements may therefore be worthy of exploration.
Elevated plasma fibrinogen levels have been found to be a strong independent risk factor for developing CVD in humans. (6) The availability of an oral fi brinogen lowering therapy may greatly enhance the management of CVD. (6) One animal study has demonstrated that bromelain had a specific activity to reduce levels of plasma fibrinogen. (7) Providing bromelain as a dietary supplement in humans could potentially provide a therapeutic opportunity which should be explored.
Bromelain is the general name for a family of sulfhydryl proteolytic enzymes obtained from Ananas comosus, the pineapple plant. (8) At present, bromelain is marketed as a dietary supplement and is available to the community in health food stores and pharmacies in Europe and the US. In China, it is approved as a registered drug and widely used clinically for reduction of inflammation, specifically thrombophlebitis.
The fi brinolytic activity of bromelain is attributed to its mechanism which appears to enhance the conversion of plasminogen to plasmin, resulting in increased fibrinolysis. (10) Bromelain's specificity is similar to that of the endogenous protease plasmin which degrades fibrin to stimulate the synthesis of anti-inflammatory prostaglandins (7) and subsequently limits the spread of the coagulation process. (11, 12) Bromelain may explain the possible mechanism linking impaired fibrinolysis and atherosclerosis associated with CVD in diabetes. (13) A systematic review suggested that there is more significant evidence from animal studies on the effect of bromelain on cardiovascular systems in animal models. (14) The review also analyzed the small number of human studies on bromelain, CVD related safety and infl ammation (carried out in the 1960's and 70's) and highlighted that study design and reporting of clinical outcomes were poor. However, it suggested the need for further research to explore and verify the effects of bromelain. (14) It was decided to carry out a randomized controlled trial (RCT). This aim of the clinical trial was to evaluate the clinical effi cacy of bromelain to reduce the risk factors associated with CVD in people with diabetes.
METHODS
This study was an exploratory prospective, randomized placebo controlled double blind, parallel design, efficacy study to assess the effects of 12 weeks of bromelain (1,050 mg/d) supplementation on plasma fibrinogen levels in people with diabetes. The study was conducted in China and was approved by the local ethical committee of Yiling Hospital Affiliated to Hebei Medical University, China, with the ethical approval number: YLLL2011[Y] 003. The trial is reported following the Consolidated Standards of Reporting Trials (CONSORT) statement guidelines (15) and registered with ClinicalTrials.gov at http://www. clinicaltrials.gov (identifi cation number NCT01524159).
Inclusion and Exclusion Criteria
Patients were included if they were: 18 years of age or older; diagnosed with type 2 diabetes, glycosylated haemoglobin (HbA 1c ) > 6.5% and had one of the following risk parameters: total cholesterol between 5.0-6.2 mmol/L, a body mass index > 25 kg/m 2 , waist circumference (WC) > 101.6 cm for men and > 88.9 cm for women, triglycerides (TG) > 1.7 mmol/L, high density lipid cholesterol (HDL-C)< 1 mmol/L for men and < 1.3 mmol/L for women, low density lipid cholesterol (LDL-C) > 2.6 mmol/L or blood pressure > 140/90 mm Hg. Exclusion criteria were: women who were pregnant or trying to conceive or lactating; subjects with severe health problems such as: renal disease, liver disease, cardiovascular disease, and other chronic health conditions; subjects currently taking warfarin, aspirin or statins; subjects already taking bromelain supplements, or other herbal supplements including Chinese medicines which may be effective e.g., cinnamon; subjects with risk factors of CVD and currently treated with any therapeutic methods; a history of allergic reactions to bee stings, olive tree pollen or pineapple; a history of occupational inhalant/skin contact with bromelain; subjects with recent diabetes ketoacidosis (past 2 weeks); unable to provide informed consent, i.e., unable to follow diet control advice or not willing to follow study procedure.
Hospital Affi liated to Hebei Medical University, China. The investigators identifi ed potential subjects attending at Yiling Hospital by assessing their recent medical reports and blood tests relating to any of the CVD risk parameters. Suitable patients based on the inclusion and exclusion criteria of the study were identifi ed and contacted by phone prior to their hospital appointment by the doctors and were informed about the study. During their hospital appointment, patients were provided with the participant information sheet and consent form. Their contents were explained by the investigators and they were invited to take part in the study. The recruitment was entirely on a voluntary basis and no one was asked to participate against his or her will. The recruited subjects were able to withdraw or dropout from the study at any time.
Randomization of Study Population
After obtaining the signed consent form which indicated the agreement to participate, the patients were randomized into the placebo or treatment group using a computer generated sequence from Statistical Analysis System (SAS) software. In this trial, randomization with allocation concealment by opaque sequentially numbered sealed envelopes was conducted.
Sample Size of Study Population
As there was no previous study on bromelain and fibrinogen on which to base a sample size calculation, this study was initiated as an exploratory trial, not powered to be definitive but to provide the basis for sample size calculation for any future trial. It was decided this study should aim to be a similar size in a review of clinical studies using bromelain as a treatment for osteoarthritis (16) and the recommendation in a pilot study using bromelain on osteoarthritis. (17) Therefore, a total of 72 subjects were recruited which would allow for a 10% dropout.
Intervention Program
Both bromelain [600 Gelatin Dissolving Units (GDU)] and placebo capsules in this study were manufactured by Jilin Province Hongjiu Biotech Co., Ltd., Ping'anchuan Developing Zone, Huinan County, Jilin Province, China, Batch No. 135118. The placebo capsule consisted of inert ingredient (wheat starch) and was indistinguishable in colour and size compared with the bromelain capsule. The capsules therefore appeared identical to study subjects. Each capsule had 350 mg of bromelain or wheat starch (placebo) and was kept in a white plastic bottle and marked A or B. The investigators, clinicians and the patients involved in this trial did not know whether bromelain or placebo capsules were contained in either bottle A or B. This was to achieve double blinding and to ensure that the investigators, clinicians and patients did not know the allocation of the capsules.
Subjects were required to take 1,050 mg (3×350 mg) of either bromelain or starch-filled placebo capsules, two (2×350 mg) after breakfast and another (350 mg) after dinner, daily for 12 weeks. Subjects were instructed to take the capsules 2 h after the meals. This was because bromelain tends to act as a digestive enzyme and its therapeutic benefi t may be diminished if taken with food. (8) The 1,050 mg dosage was chosen based on a review by Kelly (8) who suggested that the optimum effect of bromelain occurs starting at a dose of 750-1,000 mg/d for a longer period of time.
Compliance was monitored by the investigators counting the returned capsules at the end of 12 weeks. All investigators called the subjects weekly to ensure that they consumed the capsules as instructed. The compliance was recorded.
Demographic and Lifestyle Measurements
A structured questionnaire (validated and adapted for a Chinese cultural background) was used to collect subjects' information before and after the 12-week intervention. During the study, all subjects were maintained on the standard diet recommended for diabetic patients in the clinic and they were advised not to change their physical activity and lifestyle during the course of the study.
Anthropometric Measurements
Body weight was measured with patients wearing light indoor clothing and using a weighing scale with an accuracy of 0.5 kg. Standing height was recorded without shoes, on a fl at surface, with weight distributed evenly on both feet and heels together using a stadiometer to the nearest 0.5 cm. A vertical board with an attached metric rule and a horizontal headboard that could bring into contact with the uppermost point on the head was used to measure height. BMI was calculated by weight in kilograms divided by the square of height in meters (kg/m 2 ). Waist circumference was taken midway between the lower margin of the last palpable rib and the top of iliac crest to the nearest 0.5 cm. It was measured with the subject wearing light clothing, standing with feet close together, arms at the side and body weight evenly distributed.
Blood Pressure Measurements
Blood pressure was measured using a calibrated mercury sphygmomanometer and stethoscope. Two measurements were taken from the right arm with cubital fossa supported at heart level after subjects had voided, rested, and been comfortably seated for 10 min. The average of these measurements was used as the blood pressure.
Other Blood Test and Biochemical Data Measurement
All blood tests and other biochemical data were collected and tested before and after 12-week intervention in the standard laboratory in Yiling Hospital. Blood samples were collected in the morning after a 12-h fast. Fasting blood glucose (FBG), postprandial blood glucose (PPBG) and HbA 1c were measured using a rapid method NycoCard ® HbA 1c which is standardized according to the recommendation of the European Reference Laboratory (ERL) at the Diabetes Control and Complications Trial-level and is certified in accordance with the ERL Check-Up Protocol. (18) Fibrinogen level was measured with
Clauss-based functional assays using coagulation analyzer (TS4000) from MD Pacifi c Technology Co., Ltd. Tianjin, China. The operation was based on advanced photo electronic-double magnetic testing system. C-reactive protein (CRP); liver function tests included alanine transaminase (ALT) and aspartate aminotransferase (AST); kidney function tests included blood urea nitrogen (BUN) and creatinine (Cr) were measured using a Biochemistry Automatic Analyzer, model Hitachi 7180 (Hitachi High-Technologies Corporation, Tokyo, Japan). Serum total cholesterol, TG and HDL-C were analyzed on the same Hitachi 7180 Analyzer using commercial reagents. LDL-C concentrations were calculated according to the Friedewald formula.
Statistical Analysis
Statistical Package for the Social Sciences (SPSS) 16.0 for Windows was used for the statistical data analysis. Both descriptive and inferential statistics were employed to describe the quantitative data and to test whether there is a difference in change in plasma fibrinogen and other risk factors for subjects with type 2 diabetes following bromelain intervention compared to placebo group at a predetermined alpha level of 0.05, respectively.
In this study, all studied variables were found to be normally distributed based on the graphical measures using histogram and Q-Q plots ('Q' stands for quartile). Therefore, parametric tests such as independent sample t-test and paired sample t-test were performed for comparisons of means between groups and within groups respectively for the primary outcome of fibrinogen and secondary outcomes of other CVD risk factors such as blood lipid profiles, blood glucose, CRP, anthropometric indicators and blood pressures.
The treatment effect of bromelain (independent variable) on both primary and secondary outcomes (dependent variables) was further confirmed using an analysis of covariance (ANCOVA). The baseline characteristics of the respondents were used as the covariates to determine their possible influence on the dependent variables after 12-week intervention. For instance, the possible influences of extraneous variables (covariates) such as FBG, PPBG, HbA 1c , diabetes duration, CRP and age on the dependent variables, fi brinogen level after 12 weeks of intervention were statistically controlled during the analysis.
The effectiveness of bromelain was determined b y c o m p a r i n g t h e c h a n g e ( f r o m b a s e l i n e t o 12-week measurement) for the bromelain group and the change for the placebo group. This was done using an independent sample t-test carried out on the differences (week-12 minus week-0) comparing bromelain and placebo group. Independent sample t-tests were also used to compare the mean differences of other parameters (e.g., blood lipid profi les, blood glucose profi les, CRP, anthropometric indicators, blood pressure) between bromelain and placebo groups at baseline and at post-intervention. Intention-to-treat approach which provides unbiased comparisons among treatment groups (20) was used in the analysis of this RCT.
RESULTS

Participant Flow
Of the 149 subjects seen at the hospital in 3-month period, who were assessed for their eligibility for entry to the trial, 60 did not meet the inclusive criteria. A further 17 were excluded for other reasons (Figure 1) . A total of 72 subjects were recruited and randomized to either the bromelain (n=37) or the placebo group (n=35).
measures. Despite the randomisation, the difference in mean fi brinogen level was found to be statistically signifi cant between bromelain and placebo groups at the beginning of the study (P=0.012). This baseline difference means that demonstrating a significant difference as a result of bromelain intervention was problematic. The independent t-test compared the fi brinogen level reductions and indicated there was no signifi cant difference in the mean change in fi brinogen between the placebo and bromelain groups (P=0.291). Based on the ANCOVA result, the treatment effect of bromelain was not significant (P=0.293) when all the possible covariates (baseline fibrinogen, FBG, PPBG, HbA 1c , diabetes duration, CRP and age) were included in the model. Since the value obtained from the statistical analysis exceeds 0.05, there was not enough evidence to show that fibrinogen changed differently in the treatment group after 12 weeks of bromelain intervention when compared with the change in the placebo group (Table 2 ).
There were also no significant differences in mean change for blood lipids, blood glucose, CRP, anthropometric measures and blood pressure (between the bromelain and placebo groups ( Table  2) . Using ANCOVA to adjust for the possible infl uence of baseline anthropometric and biochemical characteristics on these variables at 12 weeks demonstrated that there was no effect of both groups; bromelain was no more effective than placebo with regard to these changing variables.
There were statistically significant for the difference in mean change in LDL-C (P =0.019) and PPBG (P=0.016) between the bromelain and placebo groups (Table 2) . However, the ANCOVA analysis which was used to adjust for the possible infl uence of baseline anthropometric and biochemical characteristics on these variables at 12 weeks, showed no effect of both groups. Bromelain did not show its effect with regard to changing variables compared with placebo.
There were also no statistically significant differences observed at post-intervention between groups in safety measure indicators of ALT, AST for liver and BUN and Cr for kidney.
DISCUSSION
This RCT failed to show that bromelain could There was a low dropout rate and no adverse events reported during the trial indicating the acceptability and tolerability of the treatment. Four subjects dropped out, two in the bromelain group and two in the placebo group, but this was unrelated to the trial intervention.
Baseline Characteristics of the Study Subjects
The baseline socio-demographic, lifestyle and diabetes characteristics of the study subjects are given in Table 1 . There was no difference in all the baseline characteristics among subjects apart for duration of diabetes (P>0.05). Table 2 gives data at baseline and postintervention on primary and secondary outcome Notes: others: included farmers, government servant, own business, accountant, engineer and teacher; others: included cerebral infarction, cataract, hepatic disease, overweight, cerebral haemorrhage, ulcer and prolapsed of lumber intervertebral, kidney disease, hyperthyroidism and cervical osteoarthritis. reduce fibrinogen levels among diabetic patients at risk of cardiovascular disease compared with those taking a placebo. This may have been because the majority (65.7%, n=23) of the diabetic patients at baseline already had low baseline fibrinogen levels ranging from 2.01 to 4.00 g/L. It would therefore have been diffi cult for fi brinogen levels to reduce any further, particularly for those patients with fibrinogen levels ranging between 2.01 and 3.00 g/L which represented 28.6% (n=10) diabetic patients in the bromelain group. At baseline, despite randomization there was a difference in fibrinogen levels between the two groups with those in the placebo group having a fi brinogen levels greater than 4.01 g/L. This difference at baseline may explain why there was a signifi cant drop of fi brinogen in favour of the placebo group over the bromelain group after 12 weeks intervention. Unfortunately this RCT did not screen for high fibrinogen (>4.0 g/L) at the selection or at randomization due to the additional cost required (To Be Continued) There was no signifi cant change or improvement in the blood lipid profile except LDL-C in this RCT. There was also no significant difference on the mean change in HDL-C/LDL-C ratio between groups (P=0.089). This RCT showed no improvement on blood lipids using bromelain, which is in contrast with previous studies demonstrating that the fibrinogen reduction is dependent upon lipid and lipoprotein reduction using atorvastatin. (21, 22) An animal study evaluating the effects of bromelain supplementation in laying hens on egg production reported that liver cholesterol levels were signifi cantly reduced in the bromelain supplementation group. (23) However, assessment of bromelain in an animal study does not necessarily reflect the exact situation of that in humans which may explain the failure of this RCT to demonstrate the signifi cant result of bromelain on total cholesterol.
Changes in the Study Outcomes
Bromelain had no effect on glycaemic control measured by HbA 1c . This is consistent with the fi ndings that bromelain did not signifi cantly affect any of the measured clinical parameters in volunteers in a study consisting of several patients who had myocardial infarction or stroke and with high aggregation value. (24) In the present study, for patients with type 2 diabetes, plasma glucose control (FBG and HbA 1c ) neither deteriorated nor ameliorated using bromelain. The degree of hyperglycaemia in diabetic individuals is correlated with the fibrinogen level but the effect of improving glycaemic control on fi brinogen levels is unclear. (25) This study showed no effect of bromelain on fibrinogen and glycaemic control on HbA 1c of the diabetic patients. The proposed association with hyperfibrinogenemia may contribute to the increased risk of atherosclerotic risk in diabetes due to poor glycaemic control could not be determined in this study. (25, 26) We observed no treatment effect of bromelain in FBG and HbA 1c in this study.
This study demonstrated that bromelain was no more effective than placebo at lowering CRP which in combination with fibrinogen is a signature of inflammatory processes in the body. (27) The results in this RCT contrast with the claims that bromelain has its benefi cial effects in its anti-infl ammatory properties in a number of clinical trials, particularly in joint infl ammation (17, 28, 29) as well as its importance in fi nding it effective as an adjunct in the treatment of acute thrombophlebitis due to infl ammation of a vein. (30) Since elevated CRP alone has been indicated as a marker for early bacterial infection, active rheumatoid disease, Crohn's disease and acute myocardial infarction and following trauma. (27) Individuals with diabetes tend to be pro-atherogenic which could be due to the inflammation process although the underlying mechanisms have not been fully determined, (13, 31, 32) other infl ammatory indicators such as interleukin (IL)-6 and IL-1 should be considered in future research.
Bromelain did not show any significant effect on the reduction in body weight and BMI. Unlike a previous study which showed that bromelainpancreatin combinations were effective in digestive insufficiency by increasing fat absorption and reducing faecal weight. (33) Although the association of the benefits of bromelain in blood pressure lowering treatment among diabetic patients was not evident in our current trial, this result is in support of Gutfreund, et al (34) trial which reported no change in blood pressure in humans at any dosage level, even at the high dosage of 1,840 mg. Blood pressure was measured at 0.5, 2 and 24 h after bromelain administration in this study. (34) There were a number of limitations in this study. The limitations are the disadvantage by chance of having a substantial imbalance at randomization such as the PPBG and fi brinogen levels which were significantly different at baseline between bromelain and placebo groups; variation of fi brinogen level due to different clinical laboratories practice on using different tests and assays of fi brinogen; (35) insuffi cient data from the human trials on bromelain and CVD on which to base a pre-study calculation of sample size; small sample size which may reduce the chance of demonstrating significant differences between study groups; possibility of patient compliance in consuming all capsules. In addition, the sample size was too small to reach to any defi nitive conclusions.
Using the data from this RCT carried out in a diabetic population a retrospective power calculation was conducted which takes into account the difference in mean fibrinogen level for bromelain group, difference in mean fi brinogen level for placebo group (0.36±0.91 g/L), test level (0.05) and total sample size, (72) has a power level of 33.0%, which is far less than the usual minimum power of 80% set when designing RCTs. Indeed if we had known in advance the size of differences that would be found in the RCT and used them in a sample size calculation we would have found based on this difference in mean change and SD, and using a two sided statistical test at 5% test level and 80% power, a sample size of 246 per arm would be required. (36) In conclusion, the data from this RCT failed to identify efficacy for bromelain (1.05 g/d for 12 weeks) as dietary supplement to reduce plasma fibrinogen or other risk factors associated with CVD in individuals with type 2 diabetes versus placebo. A placebo controlled trial with a larger number of people, with higher fi brinogen levels and/or individuals with a greater number of risk factors of CVD maybe a potential area for further research. The significant results obtained for the reduction of ADP-induced platelet aggregation using orally administered bromelain by Heinicke, et al (24) was not studied in this RCT due to fi nancial constraints. Changes in platelet aggregation may be a potentially useful outcome measure in future research linking bromelain with CVD risk in diabetic patients. However, it is likely that other inflammatory markers such as IL-6, IL-1 and tumour necrosis factor-alpha (TNF-α), a cytokine production, may be more promising and should be considered for inclusion as potential study outcomes in future trials since infl ammation may be the underlying mechanism between diabetes and CVD.
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